We sought to examine the real-world safety of SGLT2i vs. other newer anti-glycemic medications (DPP-4 inhibitors [DPP4i], GLP1-agonists [GLP1a]) in patients with and without CKD. Here, DPP4 is linked to chronic kidney disease.